, Volume 98, Issue 1, pp 141–143

Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats

  • S. Stevens Negus
  • Mitchell J. Picker
  • Linda A. Dykstra
Rapid Communications

DOI: 10.1007/BF00442021

Cite this article as:
Negus, S.S., Picker, M.J. & Dykstra, L.A. Psychopharmacology (1989) 98: 141. doi:10.1007/BF00442021


Buprenorphine was evaluated for its ability to act as a kappa opioid antagonist in rats responding under a fixed-ratio 30 schedule of food presentation both before and after the induction of morphine tolerance. Before the induction of morphine tolerance, both buprenorphine and the selective kappa agonist bremazocine decreased rates of responding in a dose-dependent manner, and buprenorphine (0.03 and 0.3 mg/kg) failed to antagonize bremazocine's rate-decreasing effects. Following the induction of morphine tolerance, the bremazocine dose-effect curve was unaffected, but a profound cross-tolerance developed to buprenorphine. Furthermore, buprenorphine (0.03, 0.3 and 1.0 mg/kg) produced a dose-dependent antagonism of the rate-decreasing effects of bremazocine in the morphine-tolerant rats. These results support the hypothesis that buprenorphine has antagonist activity at kappa opioid receptors.

Key words

Buprenorphine Bremazocine Kappa antagonist Morphine tolerance 

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • S. Stevens Negus
    • 1
  • Mitchell J. Picker
    • 2
  • Linda A. Dykstra
    • 2
    • 3
  1. 1.Curriculum in NeurobiologyUniversity of North CarolinaChapel HillUSA
  2. 2.Department of PsychologyUniversity of North CarolinaChapel HillUSA
  3. 3.Department of PharmacologyUniversity of North CarolinaChapel HillUSA

Personalised recommendations